FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2121568894> ?p ?o ?g. }

• W2121568894 endingPage "308" @default.
• W2121568894 startingPage "306" @default.
• W2121568894 abstract "The Oncologist 2005;10:306–308 www.TheOncologist.com Administration of bisphosphonates for cancer bone metastases, especially by the i.v. route, carries a certain, wellestablished risk of deterioration of renal function [1–9]. Although toxic acute tubular necrosis and collapsing focal segmental glomerulosclerosis have been implicated in the mechanism of renal toxicity [10–12], the pathogenesis is still poorly understood. In patients who have pre-existing chronic kidney disease (CKD) or other risk factors for the deterioration of renal function, for example, multiple myeloma, diabetes mellitus, hypertension, or advanced age, the administration of bisphosphonates is to be carried out with caution to avoid its deleterious effect on kidney function [13, 14]. Renal function monitoring guidelines have been introduced to reduce the incidence of this serious, potentially life-threatening, adverse event, and serum creatinine level measurement has been proposed as the primary parameter to assess renal risk and to provide guidance to avoid renal toxicity when zoledronic acid is administered [15]. However, excessive changes in glomerular filtration rate (GFR)—the most important parameter in assessing kidney function—correspond to only small changes in plasma creatinine concentration when patients have near normal to mildly/moderately impaired renal function [16, 17], making plasma creatinine a poor indicator of the corresponding GFR in the earlier stages of CKD. GFR must decline to approximately half the normal level before the serum creatinine concentration rises above the upper limit of normal [18]. Moreover, the plasma creatinine level underestimates renal impairment in those with reduced muscle mass, including women, children, the elderly, and the malnourished [19], many of whom have underlying malignant diseases. Therefore, serum creatinine level is not the optimal tool for establishing administration guidelines for patients treated with zoledronic acid (Zometa®; Novartis Pharmaceuticals Corporation, East Hanover, NJ, http://www.pharma.us.novartis.com), which is known to cause deterioration of renal function—defined as a ≥0.5 mg/dl increase in serum creatinine concentration in patients with normal baseline levels or a ≥1.0 mg/dl elevation in serum creatinine in patients with abnormal baseline levels (≥1.4 mg/dl)—in about 10% of patients receiving this treatment for their cancer-induced bone disease during the course of their treatment [3, 15]. Creatinine clearance and GFR predicted by the CockcroftGault formula or by the equation from the MDRD study [18, 20, 21] would offer a more reliable approach to indicate renal function impairment and to determine and monitor the stage of CKD during the overall course of zoledronic acid therapy. What is extremely worrisome is the fact that among the U.S. adult population at large there are an estimated 5.7 million people with GFRs of 60–89 ml/min per 1.73 m2, a second group of 7.4 million people with GFRs of 30–59 ml/min per 1.73 m2, and another 300,000 people with GFRs of 15–29 ml/min per 1.73 m2, many of whom have normal serum creatinine levels and are not even aware of their CKD [22]. Overall, these three groups account for 2.8%, 3.7%, and 0.13% of the U.S. adult population, respectively, The Oncologist Letter to the Editor" @default.
• W2121568894 created "2016-06-24" @default.
• W2121568894 creator A5051937204 @default.
• W2121568894 date "2005-05-01" @default.
• W2121568894 modified "2023-10-16" @default.
• W2121568894 title "The Issue of Renal Safety of Zoledronic Acid from a Nephrologist's Point of View" @default.
• W2121568894 cites W1550111394 @default.
• W2121568894 cites W1970993628 @default.
• W2121568894 cites W1995580211 @default.
• W2121568894 cites W1997629391 @default.
• W2121568894 cites W2033885211 @default.
• W2121568894 cites W2036789134 @default.
• W2121568894 cites W2055864845 @default.
• W2121568894 cites W2062417991 @default.
• W2121568894 cites W2087929119 @default.
• W2121568894 cites W2122560580 @default.
• W2121568894 cites W2130934441 @default.
• W2121568894 cites W2131217979 @default.
• W2121568894 cites W2133275623 @default.
• W2121568894 cites W2141521877 @default.
• W2121568894 cites W2151509478 @default.
• W2121568894 cites W2156376066 @default.
• W2121568894 cites W2180745593 @default.
• W2121568894 cites W2401709656 @default.
• W2121568894 cites W2607028219 @default.
• W2121568894 doi "https://doi.org/10.1634/theoncologist.10-5-306" @default.
• W2121568894 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15851781" @default.
• W2121568894 hasPublicationYear "2005" @default.
• W2121568894 type Work @default.
• W2121568894 sameAs 2121568894 @default.
• W2121568894 citedByCount "23" @default.
• W2121568894 countsByYear W21215688942012 @default.
• W2121568894 countsByYear W21215688942013 @default.
• W2121568894 countsByYear W21215688942015 @default.
• W2121568894 countsByYear W21215688942019 @default.
• W2121568894 crossrefType "journal-article" @default.
• W2121568894 hasAuthorship W2121568894A5051937204 @default.
• W2121568894 hasBestOaLocation W21215688941 @default.
• W2121568894 hasConcept C126322002 @default.
• W2121568894 hasConcept C126894567 @default.
• W2121568894 hasConcept C177713679 @default.
• W2121568894 hasConcept C2776326535 @default.
• W2121568894 hasConcept C54847362 @default.
• W2121568894 hasConcept C71924100 @default.
• W2121568894 hasConceptScore W2121568894C126322002 @default.
• W2121568894 hasConceptScore W2121568894C126894567 @default.
• W2121568894 hasConceptScore W2121568894C177713679 @default.
• W2121568894 hasConceptScore W2121568894C2776326535 @default.
• W2121568894 hasConceptScore W2121568894C54847362 @default.
• W2121568894 hasConceptScore W2121568894C71924100 @default.
• W2121568894 hasIssue "5" @default.
• W2121568894 hasLocation W21215688941 @default.
• W2121568894 hasLocation W21215688942 @default.
• W2121568894 hasOpenAccess W2121568894 @default.
• W2121568894 hasPrimaryLocation W21215688941 @default.
• W2121568894 hasRelatedWork W1991176685 @default.
• W2121568894 hasRelatedWork W2014852386 @default.
• W2121568894 hasRelatedWork W2023520015 @default.
• W2121568894 hasRelatedWork W2057208631 @default.
• W2121568894 hasRelatedWork W2101347557 @default.
• W2121568894 hasRelatedWork W2148656812 @default.
• W2121568894 hasRelatedWork W2151556292 @default.
• W2121568894 hasRelatedWork W2392413698 @default.
• W2121568894 hasRelatedWork W4252371801 @default.
• W2121568894 hasRelatedWork W2118673085 @default.
• W2121568894 hasVolume "10" @default.
• W2121568894 isParatext "false" @default.
• W2121568894 isRetracted "false" @default.
• W2121568894 magId "2121568894" @default.
• W2121568894 workType "article" @default.